Welcome to BioSeeker Group!

Triple Analysis: Pancreatic Cancer, Angiogenesis and Cancer Vaccines

Additional Information

Published Date Mar 19, 2013
Special Offer

You can deduct the full value of this report within 30 days of purchase towards a Cancer Highlights subscription.
Read more about becoming a Cancer Highlights subscriber here.

Pages 3814
PDF Fact Sheet View Fact Sheet for the report Triple Analysis: Pancreatic Cancer, Angiogenesis and Cancer Vaccines in PDF
Format PDF
Publisher BioSeeker Group
Product Line

Find the Triple Analysis Report in oncology which best suits your needs by selecting any three (3) out of these 14 high impact Cancer Focus Areas.

Availability: In stock

$3,450.00

Quick Overview

This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines.

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Angiogenesis and Cancer Vaccines.

    To find out more about Triple Analysis: Pancreatic Cancer, Angiogenesis and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Angiogenesis and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

This triple analysis focuses on cancer drug development strategies in Pancreatic Cancer and by the two mechanism/target/effect areas of Angiogenesis and Cancer Vaccines. Each of these three individual parts is evaluated according to standardized criteria in a five pillar pipeline drug assessment methodology to compare drug development strategies in oncology. This makes it easy to find and compare analysis not only within one single cancer focus area but also between different areas.

Below is a short synopsis of each part included in this report:

Part I: Pancreatic Cancer
The pancreatic cancer report part comprises defined and up to date development strategies for 247 pancreatic cancer drugs within the portfolio of 158 investigators, from Ceased to Marketed. This part extensively analyses their 197 identified drug targets, organized into 163 drug target strategies, and assesses them in eight different compound strategies.
This part is based on the following publication:
Commercializing Pancreatic Cancer Drugs: The Faster Route to Consider Your Options and Position of Others

Part II: Angiogenesis
The angiogenesis affecting cancer drug report part comprises defined and up to date development strategies for 252 drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications.
This part is based on the following publication:
Commercializing Angiogenesis Affecting Drugs in Cancer: The Faster Route to Consider Your Options and Position of Others

Part III: Cancer Vaccines
The cancer vaccine drug report part comprises defined and up to date development strategies for 196 drugs in oncology within the portfolio of 114 companies world-wide, from Ceased to Marketed. The report extensively analyses their 137 identified drug targets, organized into 114 drug target strategies, and assesses them in 52 cancer indications.
This part is based on the following publication:
Cancer Vaccines: From First-in-Class to Best-in-Class?

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug’s properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for cancer drugs to insure that the optimal market conditions exist by the time the products are commercialized.

Key Topics Covered:

Part I: Pancreatic Cancer
5.1 The Scope of this Report 27
6 Consider the Therapeutic Target Among Pancreatic Cancer Drugs for the Highest Therapeutic Outcome and Return on Investment (197 Drug Targets) 31-422
7 Emerging New Products to Established Ones: Drug Target Strategies of Pancreatic Cancer Drugs by their Highest Stage of Development (163 Drug Target Strategies and 247 Drugs) 423-612
8 Compound Strategies at Work: Competitive Benchmarking of Pancreatic Cancer Drugs by Compound Strategy (8 Compound Strategies) 613-651
9 Pipeline and Portfolio Planning: Competitive Benchmarking of the Pancreatic Cancer Drug Pipeline by Investigator (158 Investigators and 247 Drugs) 652-1088
10 Drug Index 1091
11 Company Index 1098
Figures: Includes 7 Figures
Tables: Includes 218 Tables
Total Number of Pages: 1,103

Part II: Angiogenesis
5.1 The Scope of this Report 37
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment (177 Drug Targets) 41-421
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development (170 Drug Target Strategies and 252 Drugs) 424-666
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy (7 Compound Strategies) 667-709
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology (70 Cancer Indications) 710-848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator (151 Investigators and 252 Drugs) 849-1685
12 Drug Index 1687
13 Company Index 1697
Figures: Includes 7 Figures
Tables: Includes 310 Tables
Total Number of Pages: 1,704

Part III: Cancer Vaccines
5.1 The Scope of this Report 28
6 Consider the Therapeutic Target Among Cancer Vaccine Drugs for the Highest Therapeutic Outcome and Return on Investment (137 Drug Targets) 32-245
7 First-in-Class and Me-too Analysis of Cancer Vaccine Drugs (114 Drug Target Strategies and 196 Drugs) 246-262
8 Is First-in-Class the Best-in-Class? 263-386
9 Compound Strategies at Work: Competitive Benchmarking of Cancer Vaccine Drugs by Compound Strategy (7 Compound Strategies) 387-413
10 The Competition Through Close Mechanistic Approximation of Cancer Vaccine Drugs 414-416
11 Selecting Indications for Cancer Vaccine Drugs (52 Cancer Indications) 417-492
12 Pipeline and Portfolio Planning: Competitive Benchmarking of the Cancer Vaccine Drug Pipeline by Company (114 Companies and 196 Drugs) 493-993
13 Disclaimer 994
Figures: Includes 5 Figures
Tables: Includes 239 Tables
Total Number of Pages: 1,007

This Report Includes the Following Companies:
AB Science
Abbott
AC Immune
Acceleron Pharma
Access
Active Biotech
Adaptimmune
Adherex
Advantagene
Advaxis
Advenchen
AEgera
AEterna Zentaris
Agennix
Agenus
Aida Pharmaceuticals
Alnylam
AlphaVax
Ambit Biosciences
Ambrilia Biopharma
Amgen
Amphora
Angiogen
Angiogenex
Angstrom Pharmaceuticals
Ansaris
Antisense Pharma
Antisoma
Anza Therapeutics
Apogee Biotechnology
Apotex
Arana Therapeutics
Ardea Biosciences
Argos Therapeutics
Ariad
Arno Therapeutics
ArQule
Array BioPharma
Astellas
Astex Therapeutics
AstraZeneca
Attenuon
Austrianova
AVEO
AVI BioPharma
Bavarian Nordic
Bayer
Bellicum Pharmaceuticals
Betapharma
BioAlliance Pharma
BioAxone
Biocad
Biogen Idec
Bionovo
BioNTech
BioNumerik
BioSante
Biostar
BioVex
Boehringer Ingelheim
Bolder BioTechnology
BreakThrough Therapeutics
Bristol-Myers Squibb
BTG
Calando Pharmaceuticals
Cancer Advances
Cancer Research Technology
CDG Therapeutics
Celecure
Celera
Celgene
Cell Therapeutics
CellCeutix
Celldex Therapeutics
Cellmid
Celsion
Celtic Pharma
Center of Molecular Immunology
Cephalon
CG Therapeutics
ChemoCentryx
Chemokine Therapeutics
China Sky One Medical
Choongwae
Circadian Technologies
CompleGen
Cornerstone Pharmaceuticals
Cosmo Pharmaceuticals
CreaGene
CritiTech
CSL
Cue Biotech
Curaxis
CureVac
Curis
Cyclacel
Cylene Pharmaceuticals
Cynvec
CytImmune Sciences
Cytochroma
Cytokinetics
CytRx
Daiichi Sankyo
Dainippon Sumitomo Pharma
Dara Biosciences
Deciphera Pharmaceuticals
Dendreon
DeveloGen
Dyax
EGEN Inc
Eisai
Eli Lilly
EntreMed
Epeius Biotechnologies
EpiCept
Esperance Pharmaceuticals
Etubics
Exelixis
ExonHit Therapeutics
FibroGen
Five Prime Therapeutics
Galectin Therapeutics
Galena Biopharma
GammaCan
Generex
Genmab
GenOdyssee Pharmaceuticals
Genta
Genticel
GenVec
Geron
Gilead Sciences
GlaxoSmithKline
Gliknik
GlobeImmune
GlycoGenesys
Gradalis
Green Cross
Heat Biologics
Hemispherx Biopharma
Hoffmann-La Roche
Human Genome Sciences
Hy BioPharma
Ichor Medical Systems
Idera Pharmaceuticals
ImClone Systems
immatics biotechnologies
ImmunoCellular Therapeutics
ImmunoFrontier
ImmunoGen
Immunomedics
Immunotope
Immunovaccine
ImmuPharma
Immutep
Innate Pharma
Innovive
Inovio
Insmed
Insys Therapeutics
Intracel
Introgen Therapeutics
Ipsen
ISA Pharmaceuticals
Isis Pharmaceuticals
Jennerex Biotherapeutics
Johnson & Johnson
Kadmon
KAEL-GemVax
KAI Pharmaceuticals
Karus Therapeutics
Kirin Pharma
Kringle Pharma
Kyowa Hakko Kirin
Lee’s Pharmaceutical
Leo
Lipotek
Lorus Therapeutics
Mannkind
MAT Biopharma
MBiotec
Meda
MediGene
Medisyn Technologies
Menarini
Merck & Co
Merck KGaA
Merrimack
Mersana Therapeutics
MethylGene
Micromet
MolMed
Mologen
Momotaro-Gene
Morvus Technology
Nektar Therapeutics
Nemod Biotherapeutics
Neovacs
Nereus Pharmaceuticals
NewSouth Innovations
NIH
Nippon Kayaku
Nippon Shinyaku
Non-industrial source
Northwest Biotherapeutics
Novacea
NovaLead
Novartis
NovaRx
Novelix
Novogen
Noxxon
Oasmia
OncoMed
OncoMune
Onconova
OncoTherapy Science
Oncothyreon
Oncovir
Oncozyme Pharma
Onyvax
Orchestra Therapeutics
OSI Pharmaceuticals
Oxford BioMedica
OXiGENE
Paladin Labs
PanaGin
Patrys
Pepscan Therapeutics
Peptagen
PepTx
Peregrine Pharmaceuticals
Pfizer
Pharmacopeia
Pharmacyclics
PharmaForm
PharmaMar
Pharmexa
Pharminox
Philogen
PhiloGene
Pierre Fabre
Piramal
Progen
Progenics Pharmaceuticals
ProMetic Life Sciences
Protein Sciences
Protgen
Protherics
PTC Therapeutics
Radient Pharmaceuticals
Ras Therapeutics
Reata Pharmaceuticals
Receptor BioLogix
Regeneron
Regulon
responsif
RESprotect
Rexahn
Rigel
Rottapharm Madaus
Samyang
Sanofi
Santaris Pharma
Sarepta Therapeutics
Scancell
SciClone Pharmaceuticals
Semafore Pharmaceuticals
Shionogi
Shire
Simcere Pharmaceuticals
Spear Therapeutics
SRI International
Stainwei Biotech
SuperGen
Switch Pharma
SynDevRx
Taiho
Takeda
Talon Therapeutics
Tapestry Pharmaceuticals
TapImmune
Tau Therapeutics
Teva
Thallion Pharmaceuticals
Therion Biologics
ThromboGenics
Tigris Pharmaceuticals
Titan Pharmaceuticals
ToolGen
TopoTarget
Tracon Pharmaceuticals
Tragara Pharmaceuticals
Transgene
Trion Pharma
UCB
UMN Pharma
United Biomedical
Vaccinex
Vaxil BioTherapeutics
Vaximm
Vaxon Biotech
VaxOnco
VBL Therapeutics
Vectura
Vertex Pharmaceuticals
Vical
Wilex
Vion Pharmaceuticals
VioQuest
Viragen
Virionics
ViroMed
Xerion
Yakult Honsha
YM BioSciences
Zensun
Zeria
Zydus Cadila
A Shortlist of Drugs Included are:
A6
abagovomab
ABT-510
ADXS11-001
AE-37
AEG-35156
aflibercept
AGS-003
AGS-1C4D4
AMG-386
Angiozyme
ANZ-207
apatinib
apricoxib
ARC-100
ARQ-197
astuprotimut-r
atrasentan
Auto TAG vaccine
AVX-701
axitinib
bardoxolone methyl
belagenpumatucel-L
bevacizumab
BIBF-1120
BMS-690514
bosutinib
BP-GMAX-CD1
brivanib alaninate
brivudine
BV-NSCLC-001
Cabozantinib
capecitabine
catumaxomab
CB-10-01
CDX-1307
cediranib
celecoxib
cetuximab
CG-201
cilengitide
cixutumumab
conatumumab
CPI-613
CreaVax-PC
CRLX-101
CV-9103
CV-9201
CVac
dalotuzumab
dasatinib
DCVax-prostate
DI-17E6
docetaxel
dovitinib lactate
doxorubicin
E-75
E-7820
emepepimut-S
endostatin
eniluracil
ENMD-2076
enzastaurin hydrochloride
erlotinib
everolimus
Exherin
foretinib
fosbretabulin tromethamine
ganitumab
gefitinib
GI-4000
GliaAtak
GSK-1120212
GSK-2130579A
GT-111
GV-1001
GVAX
GVX-3322
HBP-347
Her-2/Neu peptides
Hi-8 MEL
HS-110
icotinib hydrochloride
icrucumab
ICT-107
imatinib mesilate
imMucin
IMO-2055
IMP-321
interleukin-12
intetumumab
ipilimumab
IPP-204106
irinotecan
irinotecan hydrochloride
ISA-P53-01
JI-101
JX-594
KD032
L19-IL2
lapatinib ditosylate
lenvatinib
lestaurtinib
linifanib
LipoVIL12
LY-2275796
masitinib
MDX-1379
MetXia
MGCD-265
MGN-1601
midostaurin
MKC-1
mocetinostat
motesanib diphosphate
motexafin gadolinium
muparfostat (IV)
MVA-BN Her-2 vaccine
nadroparin
NGR-TNF
nimotuzumab
oblimersen sodium
olaparib
ON-01910
OncoVAX
Onyvax-105
OTS-102
P-276-00
p.DOM-WT1-37/p.DOM-WT1-126 DNA
paclitaxel
PancAtak
panobinostat
pasireotide
pasireotide LAR
pazopanib hydrochloride
PCI-27483
pegdinetanib
pemetrexed disodium
pentamidine isethionate
perifosine
PF-4856884
plitidepsin
poly-ICLC
polyclonal antibody stimulator
ponatinib
ProstAtak
PROSTVAC
PSMA ADC
PTC-299
PX-12
RAF-265
ramucirumab
regorafenib
Reximmune-C
Rexin-G
ridaforolimus
rindopepimut
rintatolimod
romidepsin
RX-0201
S-488410
SCIB-1
selumetinib
siltuximab
sipuleucel-T
sirolimus
sorafenib tosylate
ß-lapachone
SU-6668
sunitinib malate
Survivac
talactoferrin alfa
talminogene laherparepvec
TAS-102
tasquinimod
TB-403
tegafur + uracil
telatinib
temsirolimus
Tenarad
TG-4010
thymalfasin
tigatuzumab
tipapkinogene sovacivec
tipifarnib
tivozanib
tocilizumab
trabedersen
trastuzumab
TRC-105
triciribine phosphate
TroVax
TS-1
tucotuzumab celmoleukin
vandetanib
varlitinib
velimogene aliplasmid
verpasep caltespen
vismodegib
vitespen
volociximab
VX-001
WX-671
XL-184
XL-647
Z-360

Request Sample Pages or Access via 1stOncology™

  • You can request Free Sample Pages to Triple Analysis: Pancreatic Cancer, Angiogenesis and Cancer Vaccines.
    To find out more about Triple Analysis: Pancreatic Cancer, Angiogenesis and Cancer Vaccines, please read the product description below.
    We also are happy to email you out free sample pages which contain screen shots and more information on the methodology behind the product.

    Did you know that Triple Analysis: Pancreatic Cancer, Angiogenesis and Cancer Vaccines is part of the 1stOncology™ platform and can be accessed at no extra cost?

    1stOncology™ allows you to always stay on top of what is really going on in the world of cancer drug development and have an edge when it comes to Search & Evaluation, Indication Selection & Expansion, Target Scouting, First-in-Class analysis and much, much more.


    Or

Other selected research from the 'Triple Analysis' category:


Triple Analysis: Apoptosis, Protein Kinase Inhibitors and Antibodies
This triple analysis focuses on cancer drug development strategies by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors and by the compound strategy of Antibodies. Learn More


Triple Analysis: Melanoma, Apoptosis and Protein Kinase Inhibitors
This triple analysis focuses on cancer drug development strategies in Melanoma and by the two mechanism/target/effect areas of Apoptosis and Protein Kinase Inhibitors. Learn More

Other selected research from the 'Oncology' category:


Decoding Big Pharmas R&D Strategy in Oncology
This report, Decoding Big Pharma’s R&D Strategy in Oncology, is based on five major pharmaceutical companies in the oncology arena: Bristol-Myers Squibb, GlaxoSmithKline, Hoffmann-La Roche, and Sanofi-Aventis. Learn More


Triple Analysis: Leukemia, Melanoma and Cancer Vaccines
This triple analysis focuses on cancer drug development strategies in both Leukemia and Melanoma and by the mechanism/target/effect of Cancer Vaccines. Learn More